칸나비노이드 CB1 수용체 조절제로서의 4,5-디하이드로-(1H)-피라졸 유도체
    7.
    发明公开
    칸나비노이드 CB1 수용체 조절제로서의 4,5-디하이드로-(1H)-피라졸 유도체 无效
    4,5-二氢 - (1H) - 吡唑衍生物作为CANNABINOID CB1受体调节剂

    公开(公告)号:KR1020100020998A

    公开(公告)日:2010-02-23

    申请号:KR1020107000892

    申请日:2008-06-12

    摘要: This invention relates to 4,5-dihydro-(1 H)-pyrazole (pyrazoline) derivatives as cannabinoid CBreceptor modulators, to pharmaceutical compositions containing these compounds, to methods for their syntheses, methods for preparing novel intermediates useful for their syntheses, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in disorders in which CBreceptors are involved, or that can be treated via manipulation of those receptors. The compounds have formula (I) wherein the symbols have the meanings given in the specification.

    摘要翻译: 本发明涉及作为大麻素CB受体调节剂的4,5-二氢 - (1H) - 吡唑(吡唑啉)衍生物,含有这些化合物的药物组合物,其合成方法,制备用于其合成的新中间体的方法和方法 用于制备组合物。 本发明还涉及这些化合物和组合物的用途,特别是它们在给予患者以在其中涉及CB受体的病症中获得治疗效果或可以通过操纵那些受体治疗的治疗效果的用途。 化合物具有式(I),其中符号具有说明书中给出的含义。

    2-아미노에틸 치환된 피리미딘-2-온, 사이클로프로판,피라졸린, 피리미딘 및 벤조티아제핀, 및 이들의 유로텐신Ⅱ 및 소마토스타틴 5 리셉터의 리간드로서의 용도
    10.
    发明公开
    2-아미노에틸 치환된 피리미딘-2-온, 사이클로프로판,피라졸린, 피리미딘 및 벤조티아제핀, 및 이들의 유로텐신Ⅱ 및 소마토스타틴 5 리셉터의 리간드로서의 용도 无效
    2-氨基乙基取代的吡咯烷-2-酮,环戊二烯,吡咯烷酮,吡咯烷酮和苯并噻唑及其作为UROTENSIN II和SOMATOSTATIN 5受体配体的用途

    公开(公告)号:KR1020050100695A

    公开(公告)日:2005-10-19

    申请号:KR1020057015324

    申请日:2004-02-18

    发明人: 올선로저

    摘要: The present invention provides a combinatorial approach to a library of novel compounds having four diversity points. The compounds provide for the mapping of urotensin II and somatostatin 5 receptors by differential binding of said receptors. Accordingly, the invention relates in a first aspect to novel compounds of the general formula I to V or salts thereof, The present invention further relates to a method of treating diseases for which modulation of the urotensin II receptor produces a physiologically beneficial response in said disease, such as those associated with CNS function and cardiovascular diseases. The present invention further relates to pharmaceutical compositions comprising these agents for the -treatment of these diseases adapted to modulate the urotensin II receptor.

    摘要翻译: 本发明提供了具有四个分化点的新型化合物文库的组合方法。 该化合物通过所述受体的差异结合提供了尿素调节素II和生长抑素5受体的作图。 因此,本发明在第一方面涉及新的通式I至V的化合物或其盐。本发明还涉及一种治疗疾病的方法,所述疾病的调节是在所述疾病中产生生理有益的应答 ,如与CNS功能和心血管疾病相关的那些。 本发明进一步涉及药物组合物,其包含这些用于治疗适于调节前列腺素II受体的这些疾病的药剂。